Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 5, Issue 1, 2024

Near and medium term outcomes of transcatheter aortic valve replacement in elderly patients with aortic stenosis: A meta-analysis

Download as PDF

DOI: 10.23977/medsc.2024.050113 | Downloads: 7 | Views: 164

Author(s)

Guanyu Wu 1, Sheng Huo 1

Affiliation(s)

1 Queen Mary School, Medical Department, Nanchang University, Nanchang, 330031, China

Corresponding Author

Guanyu Wu

ABSTRACT

It proves that transcatheter aortic valve replacement (TAVR) is effective in aortic valve stenosis (AS), but its efficacy and safety in elder patients are controversial. We compared the near and medium-term (2 years after surgery) all-cause mortality and complications in older AS patients who underwent TAVR versus surgical aortic valve replacement (SAVR). We searched the literature on TAVR in elderly patients with AS from PubMed, Embase, and Web of Science by computer. The search period is up to August 2023. We performed a meta-analysis in the RevMan 5.3 software. We selected 16 cohort studies with 18,183 patients (9,809 received TAVR and 8,374 received SAVR). Through meta analysis, we found that in comparison with the SAVR, 1-year postoperative stroke rate of the TAVR was lower [OR=0.65, 95%CI(0.54, 0.79), P<0.001], the 2-year re-hospitalization on rate in the TAVR group was higher[OR=1.27, 95%CI(1.11, 1.46), P=0.0005], and the 2-year bleeding rate was lower [I2=18%, FEM; OR=0.55, 95%CI(0.40, 0.77), P=0.0004]. The permanent pacemaker implantation (PPI) rate at 2 years after surgery of the TAVR was higher [OR=3.03, 95%CI (1.70, 5.39), P=0.0002] and the rate of New-onset Atrial Fibrillation (NOAF) 2 years after surgery was lower [OR=0.57, 95%CI(0.40, 0.83), P=0.004]. Therefore, we conclude that the near - and medium-term efficacy of TAVR in elderly patients with AS is generally better than that of SAVR, but with a higher risk of re-hospitalization and PPI 2 years after surgery. 

KEYWORDS

Transcatheter aortic valve replacement; elderly; curative effect; security; meta-analysis

CITE THIS PAPER

Guanyu Wu, Sheng Huo, Near and medium term outcomes of transcatheter aortic valve replacement in elderly patients with aortic stenosis: A meta-analysis. MEDS Clinical Medicine (2024) Vol. 5: 77-91. DOI: http://dx.doi.org/10.23977/medsc.2024.050113.

REFERENCES

[1] Fuller SM, Borisuk MJ, Sleeper LA, Bacha E, Burchill L, Guleserian K, Ilbawi M, Razzouk A, Shinkawa T, Lu M, Baird CW. Mortality and Reoperation Risk After Bioprosthetic Aortic Valve Replacement in Young Adults With Congenital Heart Disease. Semin Thorac Cardiovasc Surg. 2021 Winter;33(4):1081-1092.
[2] Liu JD, Luo XD, Zhou ZP, Gong R, Wu YQ. Annular and supra-annular structure assessments for transcatheter aortic valve replacement in patients with bicuspid aortic stenosis. Rev Cardiovasc Med. 2021 Dec 22; 22(4):1157-1166.
[3] Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, Kotrc M, Glaveckaite S, Gasparovic H, Pavlovic N, Velicki L, Salizzoni S, Wojakowski W, Van Camp G, Nikolic SD, Iung B, Bartunek J; AVATAR Trial Investigators*. Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial. Circulation. 2022 Mar;145(9):648-658.
[4] Chao CJ, Agasthi P, Seri AR, Barry T, Shanbhag A, Wang Y, Eleid MF, Fortuin D, Sweeney JP, Pollak P, El Sabbagh A, Lester SJ, Freeman WK, Naqvi TZ, Holmes DR, Appleton CP, Arsanjani R. Transcatheter Aortic Valve Replacement Prognostication with Augmented Mean Arterial Pressure. J Cardiovasc Dev Dis. 2023 Apr 26; 10(5):192.
[5] Kuplay H, Bayer Erdoğan S, Baştopçu M, Karpuzoğlu E, Er H. Performance of the EuroSCORE II and the STS score for cardiac surgery in octogenarians. Turk Gogus Kalp Damar Cerrahisi Derg. 2021 Apr 26; 29(2):174-182. 
[6] King JM, Black MT, Jin R, Grunkemeier GL, Reynolds BR, Curtis BD, Hodson RW, Strehl EA, Gafoor SA, Forrester MD, Cox EJ, Ring ME. Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases. J Interv Cardiol. 2022 Jun 25; 2022: 9926423. 
[7] Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18; 343: d5928. 
[8] Wells G .The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in Meta-Analyses[C]//Symposium on Systematic Reviews: Beyond the Basics.2014.DOI:10.1006/bioe.2002.0137.
[9] Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, Alu MC, Madhavan MV, Chau KH, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Blanke P, Leipsic JA, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Herrmann HC, Szeto WY, Genereux P, Pershad A, Lu M, Webb JG, Smith CR, Pibarot P; PARTNER 3 Investigators. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. J Am Coll Cardiol. 2021 Mar 9;77(9):1149-1161.
[10] Søndergaard L, Steinbrüchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Ngo AT, Olsen NT, Chang Y, Franzen OW, Engstrøm T, Clemmensen P, Olsen PS, Thyregod HG. Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. Circ Cardiovasc Interv. 2016 Jun;9(6):e003665.
[11] Reardon MJ, Kleiman NS, Adams DH, Yakubov SJ, Coselli JS, Deeb GM, O'Hair D, Gleason TG, Lee JS, Hermiller JB Jr, Chetcuti S, Heiser J, Merhi W, Zorn GL 3rd, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Maini B, Mumtaz M, Conte JV, Resar JR, Aharonian V, Pfeffer T, Oh JK, Huang J, Popma JJ. Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in Patients With a Society of Thoracic Surgeons Risk Score of 7% or Less. JAMA Cardiol. 2016 Nov 1;1(8):945-949. 
[12] Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchétché D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1706-1715.
[13] Yakubov SJ, Van Mieghem NM, Reardon MJ, Serruys PW, Gada H, Mumtaz M, Deeb GM, Kodali S, George I, Windecker S, Kleiman N, Chetcuti SJ, Sanchez C, Dauerman HL, Li S, Popma JJ. Propensity-Matched Comparison of Evolut-R Transcatheter Aortic Valve Implantation With Surgery in Intermediate-Risk Patients (from the SURTAVI Trial). Am J Cardiol. 2020 Sep 15;131:82-90.
[14] Thyregod HG, Steinbrüchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrøm T, Clemmensen P, Hansen PB, Andersen LW, Olsen PS, Søndergaard L. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. J Am Coll Cardiol. 2015 May 26; 65(20):2184-94. 
[15] Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011 Jun 9; 364(23):2187-2198. 
[16] Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG; PARTNER 2 Investigators. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016 Apr 28;374(17):1609-1620.
[17] Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP; SURTAVI Investigators. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017 Apr 6;376(14):1321-1331.
[18] Amrane H, Deeb GM, Popma JJ, Yakubov SJ, Gleason TG, Van Mieghem NM, Reardon MJ; SURTAVI Trial Causes of Death Working Group. Causes of death in intermediate-risk patients: The Randomized Surgical Replacement and Transcatheter Aortic Valve Implantation Trial. J Thorac Cardiovasc Surg. 2019 Sep;158(3):718-728.e3. 
[19] Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, Herrmann HC, Kodali S, Thourani VH, Kapadia S, Svensson L, Mack MJ, Brown DL, Russo MJ, Smith CR, Webb J, Miller C, Leon MB, Cohen DJ. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation. 2019 Feb 12;139(7):877-888. 
[20] Thyregod HG, Steinbrüchel DA, Ihlemann N, Ngo TA, Nissen H, Kjeldsen BJ, Chang Y, Hansen PB, Olsen PS, Søndergaard L. No clinical effect of prosthesis-patient mismatch after transcatheter versus surgical aortic valve replacement in intermediate- and low-risk patients with severe aortic valve stenosis at mid-term follow-up: an analysis from the NOTION trial. Eur J Cardiothorac Surg. 2016 Oct;50(4):721-728.
[21] Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Lee JS, Hermiller JB Jr, Chetcuti S, Heiser J, Merhi W, Zorn GL 3rd, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Maini B, Mumtaz M, Conte JV, Resar JR, Aharonian V, Pfeffer T, Oh JK, Qiao H, Popma JJ. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2015 Jul 14;66(2):113-121.  
[22] Durko AP, Reardon MJ, Kleiman NS, Popma JJ, Van Mieghem NM, Gleason TG, Bajwa T, O'Hair D, Brown DL, Ryan WH, Chang Y, De Leon SD, Kappetein AP. Neurological Complications After Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. J Am Coll Cardiol. 2018 Oct 30;72(18):2109-2119. 
[23] Chen S, Redfors B, Ben-Yehuda O, Crowley A, Greason KL, Alu MC, Finn MT, Vahl TP, Nazif T, Thourani VH, Suri RM, Svensson L, Webb JG, Kodali SK, Leon MB. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Cardiac Surgery in the Randomized PARTNER 2A Trial. JACC Cardiovasc Interv. 2018 Nov 12; 11(21):2207-2216.  
[24] Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB; PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012 May 3;366(18):1686-1695. 
[25] Wang C, Yuan Y, Zheng M, Pan A, Wang M, Zhao M, Li Y, Yao S, Chen S, Wu S, Xue H. Association of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality. J Am Coll Cardiol. 2020 Jun 16;7 5(23):2921-2930.
[26] Dowling C, Kondapally Seshasai SR, Firoozi S, Brecker SJ. Transcatheter aortic valve replacement versus surgery for symptomatic severe aortic stenosis: A reconstructed individual patient data meta-analysis. Catheter Cardiovasc Interv. 2020 Jul;96(1):158-166. 
[27] Ahsan M, Jánosi RA, Rassaf T, Lind A. Use of extracorporeal membrane oxygenation as a bridge to transcatheter aortic valve replacement in a patient with aortic stenosis and severe coronary artery disease: a case report. Eur Heart J Case Rep. 2021 Jan 15;5(1):ytaa567.
[28] Schmidt T, Akdag O, Wohlmuth P, Thielsen T, Schewel D, Schewel J, Alessandrini H, Kreidel F, Bader R, Romero M, Ladich E, Virmani R, Schäfer U, Kuck KH, Frerker C. Histological Findings and Predictors of Cerebral Debris From Transcatheter Aortic Valve Replacement: The ALSTER Experience. J Am Heart Assoc. 2016 Nov 10; 5(11):e004399.
[29] Montalescot G, Redheuil A, Vincent F, Desch S, De Benedictis M, Eltchaninoff H, Trenk D, Serfaty JM, Charpentier E, Bouazizi K, Prigent M, Guedeney P, Salloum T, Berti S, Cequier A, Lefèvre T, Leprince P, Silvain J, Van Belle E, Neumann FJ, Portal JJ, Vicaut E, Collet JP; ATLANTIS Investigators of the ACTION Group. Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy. JACC Cardiovasc Interv. 2022 Sep 26;15(18):1794-1804. 
[30] Burke H, Boron A, Lee JH, Kahlon KR. Exploring the Difference in Post-procedural Stroke Rates Between Patients with Aortic Stenosis Who Undergo Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement. Cureus. 2018 Apr 17;10(4):e2494.  
[31] Tøndel BG, Morelli VM, Hansen JB, Braekkan SK. Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review. J Thromb Haemost. 2022 Oct;20(10):2173-2186.
[32] Berkovitch A, Segev A, Maor E, Sedaghat A, Finkelstein A, Saccocci M, Kornowski R, Latib A, De La Torre Hernandez JM, Søndergaard L, Mylotte D, Van Royen N, Zaman AG, Robert P, Sinning JM, Steinvil A, Maisano F, Orvin K, Iannopollo G, Lee DH, De Backer O, Mercanti F, van der Wulp K, Shome J, Tchétché D, Barbash IM. Clinical Predictors for Procedural Stroke and Implications for Embolic Protection Devices during TAVR: Results from the Multicenter Transcatheter Aortic Valve Replacement In-Hospital Stroke (TASK) Study. J Pers Med. 2022 Jun 28; 12(7):1056. 
[33] Donà C, Koschutnik M, Nitsche C, Winter MP, Seidl V, Siller-Matula J, Mach M, Andreas M, Bartko P, Kammerlander AA, Goliasch G, Lang I, Hengstenberg C, Mascherbauer J. Cerebral Protection in TAVR-Can We Do Without? A Real-World All-Comer Intention-to-Treat Study-Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. J Pers Med. 2022 Feb 21;12(2):320.
[34] Ding Y, Wan M, Zhang H, Wang C, Dai Z. Comparison of postprocedural new-onset atrial fibrillation between transcatheter and surgical aortic valve replacement: A systematic review and meta-analysis based on 16 randomized controlled trials. Medicine (Baltimore). 2021 Jul 16;100(28):e26613.
[35] Kim K, Ko YG, Shim CY, Ryu J, Lee YJ, Seo J, Lee SJ, Cho I, Hong SJ, Ahn CM, Kim JS, Kim BK, Hong GR, Ha JW, Choi D, Hong MK. Impact of New-Onset Persistent Left Bundle Branch Block on Reverse Cardiac Remodeling and Clinical Outcomes After Transcatheter Aortic Valve Replacement. Front Cardiovasc Med. 2022 May 27;9:893878.
[36] Auffret V, Lefevre T, Van Belle E, Eltchaninoff H, Iung B, Koning R, Motreff P, Leprince P, Verhoye JP, Manigold T, Souteyrand G; FRANCE TAVI Investigators. Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol. 2017 Jul 4;70(1):42-55.  
[37] Kapadia SR, Krishnaswamy A. Bleeding and Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2019 Dec 3; 74(22):2768-2770.
[38] Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. N Engl J Med. 2020 Jan 29;382(9):799-809.
[39] Gulsen K, Ince O, Akgun T, Demir S, Uslu A, Kup A, Ocal L, Emiroglu MY, Kargin R, Sahin I, Kepez A, Okuyan E, Ozdemir N, Kaymaz C. The effect of P wave indices on new onset atrial fibrillation after trans-catheter aortic valve replacement. J Electrocardiol. 2020 Jul-Aug;61:71-76.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4561
Visits: 197561

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.